CVD: Cardiovascular Disease Although several in-line GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs have approved indications beyond T2D and overweight/obesity, US Pharmacopeia Drug Classification (USP DC) 2025 limits classification to categories/classes according to their primary diagnosis (e.g., antidiabetic
2016 Jan;48(1):41-51
Until well-designed clinical trials are conducted, BPC-157 for bone healing should be considered investigational
These direct effects are further supported by human studies demonstrating the wide expression of GLP-1 receptors in the proximal tubules, juxtaglomerular cells, hilar and intralobular arteries, and preglomerular vascular smooth muscle cells [49]
Because tirzepatide typically produces greater total body weight loss than semaglutide, patients on tirzepatide may experience more pronounced facial volume changes than those on semaglutide at comparable timeframes
Her complete hypercoagulability workup was negative, meaning no underlying clotting disorder could be identified
